中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
15期
2271-2273
,共3页
那格列奈%瑞格列奈%糖尿病,2型%血糖
那格列奈%瑞格列奈%糖尿病,2型%血糖
나격렬내%서격렬내%당뇨병,2형%혈당
Nateglinide%Repaglinide%Diabetes,type 2%Blood glucose
目的 研究那格列奈对2型糖尿病的疗效及安全性.方法 选取2型糖尿病患者276例,按照随机数字表法分为那格列奈组138例,瑞格列奈组138例.分别给予那格列奈30 mg和瑞格列奈0.5 mg,每天3次,餐前15 min口服.12周为1个疗程.治疗前和治疗后检测空腹血糖(FBG)、餐后2h血糖(2 h PBG)、糖化血红蛋白(HbAlc)及安全性指标.结果 治疗后两组FBG、2 h PBG及HbAlc指标均较治疗前下降,差异有统计学意义(均P＜0.05).组间比较,差异无统计学意义(均P＞0.05),两组均未发生严重不良事件.结论 那格列奈能够有效控制2型糖尿病患者空腹及餐后血糖,安全可靠,值得临床推广.
目的 研究那格列奈對2型糖尿病的療效及安全性.方法 選取2型糖尿病患者276例,按照隨機數字錶法分為那格列奈組138例,瑞格列奈組138例.分彆給予那格列奈30 mg和瑞格列奈0.5 mg,每天3次,餐前15 min口服.12週為1箇療程.治療前和治療後檢測空腹血糖(FBG)、餐後2h血糖(2 h PBG)、糖化血紅蛋白(HbAlc)及安全性指標.結果 治療後兩組FBG、2 h PBG及HbAlc指標均較治療前下降,差異有統計學意義(均P＜0.05).組間比較,差異無統計學意義(均P＞0.05),兩組均未髮生嚴重不良事件.結論 那格列奈能夠有效控製2型糖尿病患者空腹及餐後血糖,安全可靠,值得臨床推廣.
목적 연구나격렬내대2형당뇨병적료효급안전성.방법 선취2형당뇨병환자276례,안조수궤수자표법분위나격렬내조138례,서격렬내조138례.분별급여나격렬내30 mg화서격렬내0.5 mg,매천3차,찬전15 min구복.12주위1개료정.치료전화치료후검측공복혈당(FBG)、찬후2h혈당(2 h PBG)、당화혈홍단백(HbAlc)급안전성지표.결과 치료후량조FBG、2 h PBG급HbAlc지표균교치료전하강,차이유통계학의의(균P＜0.05).조간비교,차이무통계학의의(균P＞0.05),량조균미발생엄중불량사건.결론 나격렬내능구유효공제2형당뇨병환자공복급찬후혈당,안전가고,치득림상추엄.
Objective To evaluate the efficacy and safety of nateglinide,a new antidiabetic agent,in the treatment of type 2 diabetes.Methods 276 patients with type 2 diabetes mellitus,in accordance with the table of random number method,were divided into the nateglinide group 138 cases,repaglinide group 138 cases.The nateglinide group was given 30 mg nateglinide,and repaglinide group was given 0.5 mg repaglinide,3 times a day,oral administration 15min before meal.12 weeks for one period of treatment.FBG,2h PBG,HbAlc and security index were detected before and after treatment.Results After treatment,FBG,2h PBG and HbAlc indexes in the two groups were lower than before treatment,the differences were statistically significant(all P ＜ 0.05).The differences were not significant compared between the two groups (all P ＞ 0.05).No serious adverse events occurred in two groups.Conclusion Nateglinide can effectively control fasting and postprandial blood sugar in patients with type 2 diabetes.It is safe and reliable and worthy clinical promotion.
